anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
TLIF (transforaminal interbody fusion) is a safe and effective treatment option for single-level lumbar degenerative disease. It is less invasive, yields good outcomes and has fewer complications after long-term follow up compared to other fusion techniques. In literature, many studies have compared sagittal parameters and functional outcomes in single-level TLIF surgery. In most literature reports, however, the fusion was performed at different lumbar levels, depending on the characteristics of the studied cohort. As demonstrated by Roussouly et. al. in the asymptomatic population, the L4 vertebra represents the apex of lumbar lordosis and is the most suitable site for lordosis correction. There are several reported surgical techniques and methods to obtain adequate lordosis correction during TLIF.

At Department of Orthopaedic surgery of Ljubljana University medical centre, TLIF is performed using a consistent brand of instrumentation. In knee-chest position, polyaxial pedicle screws (Xia®, Stryker Spine, Allendale, NJ, USA), combined with a crescent-shaped interbody cage (T-Plus®, Pioneer Surgical Technology, Marquette, MI, USA), bilateral facet joint removal and laminectomy on both sides are used. Compression over the rods is performed to obtain adequate segmental lordosis. The angle of lordosis correction is calculated according Schwab's formula (ideal lumbar lordosis (LL) = pelvic incidence (PI) + 9).

There is little published information regarding cohorts with long-term evaluation. As many authors suggested, changes in lordotic parameters can become clinically evident several years after the procedure. With this study's cohort analysis, a rarely reported link between spinopelvic parameters and long-term clinical evaluation will be demonstrated. Selected participants will be analyzed using the same protocol as preoperatively. A clinical examination will be made, ODI questionnaires will be administered and radiographic parameters on full-standing lateral radiographs, will be analyzed. Changes between preoperative and long-term postoperative parameters will be calculated and compared. For statistical analysis paired t-test and Pearson correlation will be used. All statistical tests will be two tailed and significance will be set at p\<0.05.
OBJECTIVE: To investigate the impact of the glucagon-like peptide-1 (GLP-1) receptor agonist Exendin-4 on the proportion of myeloid-derived suppressor cells (MDSCs) in male ApoE-/- mice, and investigate alterations in the concentrations of inflammatory factors in plasma and spleen tissues and assess their correlation with MDSCs.
METHODS: Thirty male ApoE-/- mice were randomly divided into five groups (n = 6 per group): control group (CON), model group (MOD), Exendin-4 intervention group (MOD/Ex-4), Exendin-9-39 intervention group (MOD/Ex-9-39), and Exendin-4 + Exendin-9-39 combined intervention group (MOD/Ex-4 + Ex-9-39). After 4 weeks of drug intervention, changes in aortic plaque were observed using Oil Red O staining and H&E staining. Flow cytometry was employed to detect the content of myeloid-derived suppressor cells (MDSCs) in bone marrow and peripheral blood. ELISA was utilized to measure the concentrations of inflammatory factors in mouse peripheral blood plasma, while RT-qPCR was employed to quantify the expression levels of inflammatory factors in the spleen. Pearson correlation analysis was conducted to assess the relationship between MDSCs and inflammatory factors.
RESULTS: Mice in the MOD group had significantly higher body weight compared to the CON group, with a statistically significant difference (P<0.05). Following Exendin-4 intervention, body weight was reduced compared to the MOD group (P<0.05). Additionally, Exendin-4 treatment led to a significant reduction in atherosclerotic plaque compared to the MOD group (P<0.001). After Exendin-4 intervention, the proportion of MDSCs in the bone marrow was higher than in the MOD group (P<0.001), and the proportion of MDSCs in peripheral blood was significantly higher than in the MOD group (P<0.05). Further investigation revealed that Exendin-4 could regulate lipid levels in mice, decreasing concentrations of TG (P<0.01), TC (P<0.0001), and LDL-C (P<0.0001), while increasing HDL-C concentrations (P<0.01). Moreover, after Exendin-4 treatment, the level of the cytokine IL-6 in peripheral plasma was significantly lower compared to the MOD group (P<0.0001), while levels of IL-10 and TGF-β were significantly higher compared to the MOD group (P<0.0001). In the spleen, levels of the cytokines IL-10 (P<0.0001) and TGF-β (P<0.001) were significantly increased compared to the MOD group. Pearson correlation analysis showed that the proportion of MDSCs in peripheral blood was positively correlated with IL-10 and TGF-β levels in both the spleen and peripheral blood. Additionally, the proportion of MDSCs in the bone marrow was positively correlated with IL-10 and TGF-β levels in the spleen and peripheral blood.
CONCLUSION: Exendin-4 alleviates the severity of atherosclerosis. This process may be achieved by promoting the secretion of myeloid-derived suppressor cells (MDSCs) in the bone marrow and peripheral blood of atherosclerotic ApoE-/- mice, regulating the ratio of inflammatory factors in the body, reducing mouse body weight, and lowering blood lipids.
BACKGROUND: The interplay between chronic kidney disease (CKD) and thyroid dysfunction is becoming more evident in the biomedical community. However, the intricacies of their relationship warrant deeper investigation to understand the clinical implications fully.
OBJECTIVE: This study aims to systematically evaluate the correlation between thyroid hormone levels, including thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxine (T4), and markers of renal disease severity. These markers include serum creatinine, urea, and parathyroid hormone (PTH) levels in individuals diagnosed with CK).
METHODS: We conducted a cross-sectional observational study involving a cohort of 86 participants with CKD recruited from the renal clinic at King Fahad Hospital in Tabuk. Biochemical parameters, encompassing plasma electrolytes and thyroid hormone concentrations, were quantitatively assessed. These measurements were performed with the aid of a Roche Cobas E411 analyzer. The Pearson correlation coefficient was employed to delineate the strength and direction of the associations between the thyroid function markers and renal disease indicators.
RESULTS: The statistical analysis highlighted a generally weak correlation between the concentrations of thyroid hormones and the indicators of renal disease severity, with Pearson correlation coefficients between -0.319 and 0.815. Critically, no significant correlation was found between creatinine and thyroid hormones (TSH, T3, T4), nor was any substantial correlation between urea and thyroid hormones. Conversely, a robust positive correlation was noted between the levels of parathyroid hormone and serum creatinine (r = 0.718, p < 0.001).
CONCLUSION: The data suggests that thyroid hormone levels have a minimal correlation with the severity of renal disease markers. In contrast, the pronounced correlation between PTH and creatinine underscores the importance of considering PTH as a significant factor in managing and therapeutic intervention of CKD complications. These initial findings catalyze further research to thoroughly investigate the pathophysiological relationships and potential therapeutic targets concerning thyroid dysfunction in patients with renal impairment.
The invention belongs to the biotechnology and the medical field and discloses a new human epididymal specific expression sperm binding protein HEL-213 as well as preparation and application thereof. The invention discloses an amino acid sequence of the HEL-213 protein and provides a recombinant expression vector which carries a DNA sequence used for encoding the protein. The protein is located in an acrosomal region of a mature sperm, has higher expression level in the head and the body of an epididymis, a testis, a heart, a liver, a spleen and a kidney and has no expression in a stomach tissue. A band of about 20 KD is detected in the epididymis by using Western blot. The HEL-213 protein can be used as a target protein for developing an immunological contraceptive and clinically diagnosing and treating male infertility. A method for detecting a corresponding gene or protein based on development of the HEL-213 protein can be widely used for the research field of reproductive medicine.
PCT No. PCT/EP91/01706 Sec. 371 Date May 6, 1992 Sec. 102(e) Date May 6, 1992 PCT Filed Sep. 13, 1991 PCT Pub. No. WO92/05806 PCT Pub. Date Apr. 16, 1992.A viscous solution of a filmogenic protein is whipped into a foam and the foam is subjected to shear to reduce the size of the foam bubbles to a range (about 0.5-10  mu m) suitable for echography. The proteins include animal and vegetal proteins or partial hydrolyzates thereof with foaming properties. The suspensions of microspheres can be stabilized by heat or by cross-linkers.
Participants will take daily oral dose of PLX3397 for 28 day cycles. Participants will continue to take PLX3397 until disease progression or toxicity.
The invention discloses an antihypertensive traditional Chinese medicine and a preparation method therefor. The raw material formula of the antihypertensive traditional Chinese medicine comprises 25-35 parts of abalone shell, 20-30 parts of uncaria, 20-30 parts of root of kudzu vine, 20-30 parts of prunella vulgaris, 10-15 parts of ligusticum wallichii, 10-15 parts of loranthus parasiticus, 10-15 parts of eucommia ulmoides, 10-15 parts of cortex moutan, 10-15 parts of scutellaria baicalensis, 10-15 parts of wild chrysanthemum flowers, 10-15 parts ofrhizoma gastrodiae, 10-15 parts of lumbricus, 10-15 parts of dutchmanspipe root, 5-10 parts of apocynum venetum, 5-10 parts of harlequin glorybower leaves and 5-10 parts of coptis. The preparation method is as follows: the raw materials are crushed to 80-120 meshes, and then are decocted in water twice. For the first time, water with a weight of 8-10 times is added and heated to boiling and the boiling is sustained for 1-2 h. For the second time, water with a weight of 6-8 times is added and heated to boiling and the boiling is sustained for 0.5-1h. After each decoction, filtration is carried out and filtrates are obtained, then the filtrates are mixed and packaged in bags, and the antihypertensive traditional Chinese medicine is obtained. The raw materials of the antihypertensive traditional Chinese medicine have wide source. The preparation method is simple and easy to control. The prepared antihypertensive traditional Chinese medicine is natural, has no toxic or side effects, and can treat and relieve hypertension effectively.
The non M/XDR-TB cohort will consist of patients with no suspected infection with an M/XDRTB strain. The suspicion will be out ruled on behalf of molecular biological methods (i.e.GeneXpert, detection of rifampicin resistance with high probability of simultaneous isoniazid resistance). The non M/XDR-TB cases will be confirmed by culture (n= 20). Empirically, about 90% of these patients have no drug resistance against first line drugs.
The present disclosure provides for CAR Tregs and Tregs which are both conversion-resistant,  i.e. , resistant conversion to effector T cells, and condition-resistant, i.e., resistant to a T cell-depleting conditioning regimen involving an antibody, in some instances an anti-CD2 antibody. The disclosed Treg cells are engineered such that they are deficient in or substantially devoid of a cell-surface marker or antigen,  i.e. , the entire or portion of the gene encoding the cell-surface marker or antigen is deleted from the Treg cell. In some instances, the cell-surface marker or antigen is CD2. The CAR Tregs can comprise a first nucleic acid construct encoding a chimeric antigen receptor (CAR). The present disclosure also provides for a one-step method for producing such conversion-resistant/condition-resistant CAR Tregs and Tregs, using an RNA-guided nuclease. The present disclosure also provides for compositions including pharmaceutical compositions comprising the cells, and use of the cells and compositions for therapeutic, prophylactic and diagnostic methods.
Randomly selected participants will receive 20 min. of anodal transcranial direct current stimulation to the the top of their heads. The current will slowly be ramped up over 30 secs.
PURPOSE:To obtain a freeze-dried drug preparation having improved solubility and stability after the storage over a long period and useful as an antitumor agent, by adding a soluble protein and polysaccharide as constituent components to a polyriboinosinic acid.polyribocytidylic acid.poly-L-lysine complex. CONSTITUTION:A freeze-dried drug preparation composed of a polyriboinosinic acid.polyribocytidylic acid.poly-L-lysine complex is added with a soluble protein and/or polysaccharide as constituent components. The soluble protein is gelatin, collagen or serum albumin or a mixture of two or more of the above proteins. The polysaccharide is dextrin, dextran, chondroitin sulfate or a mixture of two or more of the polysaccharides. The amounts of the soluble protein and the polysaccharide are preferably 0.3-30pts.wt., and 0.1-30pts.wt. per 1pt.wt. of the complex, respectively.
In adult clinical trials in patients with narcolepsy (n=781), there were two suicides and two attempted suicides in patients treated with Sodium Oxybate Oral Solution, including three patients with a previous history of depressive psychiatric disorder. Of the two suicides, one patient used Sodium Oxybate Oral Solution in conjunction with other drugs. Sodium Oxybate Oral Solution was not involved in the second suicide. Adverse reactions of depression were reported by 7% of 781 patients treated with Sodium Oxybate Oral Solution, with four patients (<1%) discontinuing because of depression. In most cases, no change in Sodium Oxybate Oral Solution treatment was required.

In a controlled adult trial, with patients randomized to fixed doses of 3 g, 6 g, or 9 g per night Sodium Oxybate Oral Solution or placebo, there was a single event of depression at the 3 g per night dose. In another adult controlled trial, with patients titrated from an initial 4.5 g per night starting dose, the incidences of depression were 1 (1.7%), 1 (1.5%), 2 (3.2%), and 2 (3.6%) for the placebo, 4.5 g, 6 g, and 9 g per night doses, respectively.

In the pediatric clinical trial in patients with narcolepsy (n=104), one patient experienced suicidal ideation and two patients reported depression while taking Sodium Oxybate Oral Solution.

The emergence of depression in patients treated with Sodium Oxybate Oral Solution requires careful and immediate evaluation. Patients with a previous history of a depressive illness and/or suicide attempt should be monitored carefully for the emergence of depressive symptoms while taking Sodium Oxybate Oral Solution.
PURPOSE:To obtain a drug having improved bioavailability, by esterifying the carboxyl of a drug having a carboxyl group with a novel 1,3-dioxolen-2-one derivative, a modifying agent for a prodrug of a drug. CONSTITUTION:A drug such as ampicillin, etc. having a carboxyl group is reacted with a 1,3-dioxolen-2-one derivative (e.g., 4-bromomethyl-5-methyl-1,3-dioxolen-3-one, etc.) shown by the formulaI(R<1> is H, lower alkyl, or aryl; R<2> is H or R<1> and R<2> may be linked to form a ring; X is halogen), so that the caboxyl is esterified to give a drug having improved bioavailability. The novel compound shown by the formulaI, for example, is prepared by reacting a compound shown by the formula II with a halogenating agent under conditions to produce a radical. EFFECT:Esterification of the drug makes it stable in gastric juice and intestinal juice. When it is absorbed in the intestine, it is hydrolyzed by the action of an enzyme in the body, restored to the original compound, and shows medicinal effects.
Pinhole surgery with orthodontic buttons The selected participants were assigned in test and control. In the test group orthodontic buttons were cemented on the bid-buccal region of the crown with dual cure GIC. After administration of LA, 2 to 3 pinhole incisions were made and a full thickness muco-periosteal tunnel was raised and collagen membrane was tucked in through the pinhole incisions. The sling sutures 5-0 mersilk were placed to hold the tunnel in an advanced location using orthodontic buttons as anchoring units. Inter-dental sutures with 6-0 mersilk were also placed for stabilization of the advanced gingival tissue.
Gelled ester compositions are provided. The gelled esters are obtained by mixing a suitable ester with one or more triblock copolymers, star polymers, radial polymers, multi-block copolymers, or mixtures thereof. Optionally, one or more diblock copolymers can be used in forming the gel compositions. In addition to gelled esters, gelled alcohols, gelled ethers, and gelled naturally-occurring fats and oils also are obtained by using one or more diblock copolymers, triblock copolymers, star polymers, radial polymers, multi-block copolymers, or mixtures thereof as a gelling agent. Butyl rubbers and alkyl galactomannan also can be used as a gelling agent. The gel compositions may be used to suspend various solids and/or liquids.
The laryseal pro could provide rapid and secure airway management and improve patient safety with gastric access reducing the risk of pulmonary aspiration, in addition to speeding up the ETT tube placement with a unique guide system, beside to integrated fenestrated flap that protects from blockage with minimal increase in flow resistance, and elevates the epiglottis for easy, trauma-free ETT tube or bronchoscope insertion. According to the manufacturer: all these features of laryseal pro allow quick easy first time insertion success. As, the laryseal pro is being of shorter breathing tube and smaller cuff in comparison to Air-Q Blocker, so the laryseal pro is expecting to be more amazing than the Air-Q Blocker especially for the new trainers regarding the total insertion time of the endotracheal tube and success rate. Jatin et al. 2021reported that Air-Q Intubating Laryngeal Airway resulted in significantly more success rate and ease of intubation as compared to Ambu Aura Gain. Andrzej et al. 2018 stated that success rate of blind intubation through Air-Q was 75% when compared to 80% in I-gel group. In contrary, there are limited studies available in literature on blind tracheal intubation through the laryseal pro.
The invention concerns a method for conducting business at a medical practice. The method includes acquiring a customizable medical database containing information about medical conditions, and personalizing the database with details of the medical practice. The method further includes providing consultations at the medical practice, including identification of a patient's condition. The method further includes selecting subject matter relevant to the patient's condition in a database query and printing an information sheet from the database in response to the query. The information sheet is automatically personalized to identify the medical practice and to contain information about the patient's condition. The invention further concerns a customizable database containing information about medical conditions. The database is operable to personalize it with details of a medical practice and to select subject matter relevant to a patient's condition in a database query so that an information sheet can be selectively printed from the database in response to the query. The information sheet is automatically personalizable to identify the medical practice and information about the patient's condition.
PROBLEM TO BE SOLVED: To obtain a deodorization active material suitable for an aerosol type cosmetic capable of exhibiting excellent antiperspirant action by solving problems such as the corrosion of aerosol cans when aluminum hydrochloride having excellent action effect as an antiperspirant is used as the antiperspirant. SOLUTION: A calcium phosphate based combined particle contains calcium phosphate based particle and aluminum hydrochloride and the calcium phosphate based particle is an amorphous calcium phosphate based particle. In the synthesis of the amorphous calcium phosphate based particle by adding a phosphoric acid aq. solution in a suspension containing 1-20 wt.% calcium hydroxide and adjusting pH 5-11, aluminum hydrochloride is added in an amorphous calcium phosphate slurry obtained by controlling the temp. of the suspension at the time of being synthesized not to exceed 50 deg.C, mixed and granulated while being dried. The aerosol type cosmetic contains the calcium phosphate based particle.
Tenecteplase is a tissue plasminogen activator (tPA) produced by recombinant DNA technology using a mammalian cell line (Chinese Hamster Ovary cells). Tenecteplase is a 527-amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296–299 in the protease domain. It has a molecular weight of 58,742 daltons. Biological potency is determined by an in vitro clot lysis assay and is expressed in tenecteplase specific units. The specific activity of tenecteplase has been defined as 200 units/mg.

TNKase (tenecteplase) for injection is a sterile, white to pale yellow, lyophilized powder for intravenous bolus administration after reconstitution with Sterile Water for Injection, USP. Each single-dose vial of TNKase nominally contains 50 mg of tenecteplase, arginine (522 mg), phosphoric acid (approximately 160 mg), and polysorbate 20 (4.0 mg). Following reconstitution with the supplied 10 mL single-dose vial of Sterile Water for Injection, USP, the final concentration is 5 mg/mL with a pH of approximately 7.3.
In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
Introduction Hysterectomy is the most commonly performed gynecological operation and can be carried out through various methods using a wide array of instruments and energy techniques. Although the methods have advantages and disadvantages over each other, minimally invasive procedures are associated with less morbidity and perioperative recovery. Recent advancements in surgical tools and methodologies have facilitated endoscopic surgeries. Uterine manipulation is crucial in laparoscopic hysterectomy as it facilitates bladder dissection, positioning the ureters, and exposing the anterior and posterior vaginal fornices. It also maintains pneumoperitoneum. Currently, many uterine manipulators are available, but the evidence for their efficacy and safety is still unclear. The purpose of utilizing a uterine manipulator is to enhance surgical outcomes and reduce intraoperative complications, particularly concerning the bladder and ureter. It is important to visualize the anterior and posterior fornices and ensure maintenance of the pneumoperitoneum. Therefore, uterine manipulators play a crucial role in laparoscopic hysterectomy. However, none of the manipulators currently available possess all the characteristics of an ideal manipulator. Therefore, the investigators aimed to compare the Vcare and SecuFix uterine manipulators used in laparoscopic hysterectomy with regard to operative time, length of hospital stay, estimated blood loss, and perioperative complications.